IMCR News & Events

Immunocore announced updated results from its Phase 1/2 trial evaluating brenetafusp in patients with heavily pretreated advanced melanoma. The data is presented in a poster at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting. In the 66 patients treated with brenetafusp monotherapy, the median overall survival was 14.3 months with a landmark OS rate of 87% at 6 months and 57% at 12 months. The disease control rate was 52%, while the overall response rate was 12%. Multiple measures of clinical benefit were numerically higher for patients treated with the 160 mcg dose - despite worse baseline prognostic factors compared to those treated with 40 mcg. These data support selection of 160 mcg for the ongoing Phase 3 trial evaluating brenetafusp + nivolumab vs. standard nivolumab regimens in first-line advanced melanoma. The safety profile was similar at both doses. Brenetafusp was generally well tolerated, showing a predictable, mechanism-driven safety profile as monotherapy and in combination.

Reports Q1 revenue $106.68M, consensus $107.08M. "We are proud to report another quarter of strong commercial performance, with KIMMTRAK generating $107 million in net revenues in Q1 2026," said Bahija Jallal, CEO of Immunocore. "The five-year overall survival (OS) data from our Phase 3 trial presented at AACR is a landmark moment. It is the longest OS follow-up ever reported in a randomized trial in metastatic uveal melanoma and underscores the long-term benefit KIMMTRAK delivers to patients. In parallel, we are executing with discipline across our pipeline."

Immunocore announced that Kimmtrak five-year overall survival, OS, was presented in an oral session at the American Association for Cancer Research, AACR, 2026 meeting. This is the longest, prospective Phase 3 randomized trial in patients with unresectable or metastatic uveal melanoma - a disease with a very poor prognosis and a historical survival rate of less than 5% at 5 years. Kimmtrak doubled the likelihood of being alive at five years, with an OS for Kimmtrak of 16% versus 8% in the control arm. These results also represent the longest follow-up reported for any T cell engager in a solid tumor.